Vivek Ramaswamy

“Roivant does not view - and has never viewed - Axovant as simply a 'vehicle' for developing intepirdine, but instead as a platform for the development of high-impact drugs in dementia and the neuroscience field more generally.”

“I would not have had the same personal commitment to Alzheimer's disease if it had not been for my mother and my upbringing.”

“There is no doubt that the Mindset failure is a major setback for Axovant, but it is not the end of the road.”

“The 'Living-Wage Campaign' at Harvard is like a Boston winter: you know it's going to strike, but wonder only when and how hard.”

“The problem we are trying to solve is that of drugs that would have never seen the light of day for reasons that have nothing to do with the inherent properties of drug candidates themselves and more to do with bureaucratic institutions within which they often sit.”

“From a personal standpoint, I consider myself much more of an accidental entrepreneur. I was involved in the entrepreneurship club at Harvard, but I heard of it only because it was new on campus.”